{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T20:10:01Z","timestamp":1773519001080,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This systematic review and network meta-analysis (NMA) evaluated the efficacy and safety of dual antiplatelet therapy (DAPT) and triple antiplatelet therapy (TAPT) in East Asian patients with acute coronary syndrome. Twenty-six randomized controlled trials comparing DAPT (P2Y12 inhibitor with aspirin) or TAPT (cilostazol with clopidogrel-based DAPT) were included from four databases. Primary outcomes were major adverse cardiac events (MACEs) and major bleeding events. Frequentist NMA was performed using RRs. The reference comparator was clopidogrel-based DAPT. TAPT significantly reduced MACEs without increasing major bleeding events. Standard-dose potent P2Y12 inhibitor-based DAPT showed no MACE reduction but significantly increased major bleeding events. TAPT had the highest probability of reducing MACEs, while DAPT incorporating potent P2Y12 inhibitors with de-escalation had the highest probability of minimizing major bleeding events. To conclude, TAPT demonstrates promising efficacy without compromising safety, while de-escalation strategies appear effective in balancing the efficacy and safety of DAPT.<\/jats:p>","DOI":"10.1093\/postmj\/qgag031","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:42:30Z","timestamp":1772109750000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of dual and triple antiplatelet therapies in East Asian patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-8877","authenticated-orcid":false,"given":"Jonathan Ka-ming","family":"Ho","sequence":"first","affiliation":[{"name":"School of Nursing and Health Sciences, Hong Kong Metropolitan University , 1 Sheung Shing Street, Homantin, Kowloon,","place":["Hong Kong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel Ka-man","family":"Chow","sequence":"additional","affiliation":[{"name":"School of Nursing and Health Sciences, Hong Kong Metropolitan University , 1 Sheung Shing Street, Homantin, Kowloon,","place":["Hong Kong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-2685","authenticated-orcid":false,"given":"Timothy Chung-ming","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Nursing and Health Sciences, Hong Kong Metropolitan University , 1 Sheung Shing Street, Homantin, Kowloon,","place":["Hong Kong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona Yuen-ling","family":"Leung","sequence":"additional","affiliation":[{"name":"School of Nursing and Health Sciences, Hong Kong Metropolitan University , 1 Sheung Shing Street, Homantin, Kowloon,","place":["Hong Kong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hon-lon","family":"Tam","sequence":"additional","affiliation":[{"name":"The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong ,","place":["Hong Kong, Shatin, New Territories, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Tse","sequence":"additional","affiliation":[{"name":"School of Nursing and Health Sciences, Hong Kong Metropolitan University , 1 Sheung Shing Street, Homantin, Kowloon,","place":["Hong Kong, China"]},{"name":"Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University , 23 Pingjiang Road, Hexi District, Tianjin ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"2026031412100690700_ref1","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026031412100690700_ref2","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001309","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"2026031412100690700_ref3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2026031412100690700_ref4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026031412100690700_ref5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"2026031412100690700_ref6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026031412100690700_ref7","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2026031412100690700_ref8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The east Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026031412100690700_ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5546260","article-title":"Clinical outcome between ticagrelor versus clopidogrel in patients with acute coronary syndrome and diabetes","volume":"2021","author":"He","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"2026031412100690700_ref10","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"Park","year":"2019","journal-title":"Circulation"},{"key":"2026031412100690700_ref11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2147\/TCRM.S108965","article-title":"Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome","volume":"12","author":"Wang","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2026031412100690700_ref12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/FJC.0000000000000390","article-title":"Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"68","author":"Tang","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026031412100690700_ref13","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"Saito","year":"2014","journal-title":"Circ J"},{"key":"2026031412100690700_ref14","doi-asserted-by":"publisher","first-page":"056","DOI":"10.1055\/s-0042-1746417","article-title":"Infarct size and long-term clinical outcomes of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing coronary artery stenting: a prospective randomized study","volume":"32","author":"Yabe","year":"2023","journal-title":"Cardiovasc Interv Ther"},{"key":"2026031412100690700_ref15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/jcm10061159","article-title":"Temporal trends of bleeding episodes during half- vs. standard-dose ticagrelor in acute coronary syndrome patients with low platelet reactivity: a randomized BLEEDING-ACS trial","volume":"10","author":"Kim","year":"2021","journal-title":"J Clin Med"},{"key":"2026031412100690700_ref16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/clc.23517","article-title":"Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction","volume":"44","author":"Wang","year":"2021","journal-title":"Clin Cardiol"},{"key":"2026031412100690700_ref17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"2026031412100690700_ref18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1055\/a-1346-3300","article-title":"Pharmacodynamic profile and prevalence of bleeding episode in east Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial","volume":"121","author":"Jeong","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026031412100690700_ref19","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.3390\/jcm10122699","article-title":"Pharmacodynamics and outcomes of a de-escalation strategy with half-dose prasugrel or ticagrelor in east Asians patients with acute coronary syndrome: results from HOPE-TAILOR trial","volume":"10","author":"Jin","year":"2021","journal-title":"J Clin Med"},{"key":"2026031412100690700_ref20","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of Ticagrelor monotherapy vs Ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"2026031412100690700_ref21","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"2026031412100690700_ref22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"2026031412100690700_ref23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026031412100690700_ref24","doi-asserted-by":"publisher","first-page":"e082945","DOI":"10.1136\/bmj-2024-082945","article-title":"Stepwise dual antiplatelet therapy de-escalation in patients after drug coated balloon angioplasty (REC-CAGEFREE II): multicentre, randomised, open label, assessor blind, non-inferiority trial","volume":"388","author":"Gao","year":"2025","journal-title":"BMJ"},{"key":"2026031412100690700_ref25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"2026031412100690700_ref26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jcph.1988","article-title":"Update on cilostazol: a critical review of its antithrombotic and cardiovascular actions and its clinical applications","volume":"62","author":"Manolis","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2026031412100690700_ref27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00380-010-0093-1","article-title":"Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up","volume":"26","author":"Ahn","year":"2011","journal-title":"Heart Vessel"},{"key":"2026031412100690700_ref28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ahj.2009.01.006","article-title":"Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study","volume":"157","author":"Han","year":"2009","journal-title":"Am Heart J"},{"key":"2026031412100690700_ref29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.amjcard.2017.11.005","article-title":"Comparison of 1-year outcomes of triple (aspirin + clopidogrel + cilostazol) versus dual antiplatelet therapy (aspirin + clopidogrel + placebo) after implantation of second-generation drug-eluting stents into one or more coronary arteries: from the DECREASE-PCI trial","volume":"121","author":"Lee","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026031412100690700_ref30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ahj.2023.06.015","article-title":"Efficacy and safety of cilostazol-based triple antiplatelet therapy compared with clopidogrel-based dual antiplatelet therapy in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a multicenter, randomized, open-label, phase 4 trial","volume":"265","author":"Park","year":"2023","journal-title":"Am Heart J"},{"key":"2026031412100690700_ref31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2147\/TCRM.S86799","article-title":"Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary intervention","volume":"11","author":"Wang","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2026031412100690700_ref32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"Valgimigli","year":"2024","journal-title":"Lancet"},{"key":"2026031412100690700_ref33","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026031412100690700_ref34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jphys.2019.08.005","article-title":"Clinimetrics: physiotherapy evidence database (PEDro) scale","volume":"66","author":"Cashin","year":"2020","journal-title":"J Physiother"},{"key":"2026031412100690700_ref35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res Synth Methods"},{"key":"2026031412100690700_ref36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"2026031412100690700_ref37","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J"},{"key":"2026031412100690700_ref38","first-page":"793","article-title":"A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation","volume":"122","author":"Han","year":"2009","journal-title":"Chin Med J"},{"key":"2026031412100690700_ref39","first-page":"13310","article-title":"A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with cyp2c19*2 homozygotes","volume":"8","author":"Xiong","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2026031412100690700_ref40","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4314\/tjpr.v19i3.29","article-title":"Comparison of the efficacy of half ticagrelor loading doses and clopidogrel in elderly acute coronary syndrome patients in China","volume":"19","author":"Xue","year":"2020","journal-title":"Trop J Pharm Res"},{"key":"2026031412100690700_ref41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jacasi.2025.04.010","article-title":"Position statement on antiplatelet therapy for east Asians with coronary artery disease: 2025 update","volume":"5","author":"Gong","year":"2025","journal-title":"JACC Asia"},{"key":"2026031412100690700_ref42","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1093\/eurheartj\/ehv304","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"2026031412100690700_ref43","doi-asserted-by":"publisher","first-page":"e019630","DOI":"10.1161\/JAHA.120.019630","article-title":"Factors related to major bleeding after ticagrelor therapy: results from the TICO trial","volume":"10","author":"Cho","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026031412100690700_ref44","doi-asserted-by":"publisher","first-page":"e011990","DOI":"10.1161\/CIRCINTERVENTIONS.122.011990","article-title":"Comparison of unguided de-escalation versus guided selection of dual antiplatelet therapy after acute coronary syndrome: a systematic review and network meta-analysis","volume":"15","author":"Kuno","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"2026031412100690700_ref45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacc.2021.06.012","article-title":"De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes","volume":"78","author":"Shoji","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026031412100690700_ref46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/2230-8210.179990","article-title":"Study of differences in presentation, risk factors and management in diabetic and nondiabetic patients with acute coronary syndrome","volume":"20","author":"Sharma","year":"2016","journal-title":"Indian J Endocrinol Metab"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article-pdf\/doi\/10.1093\/postmj\/qgag031\/67358047\/qgag031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article-pdf\/doi\/10.1093\/postmj\/qgag031\/67358047\/qgag031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:10:11Z","timestamp":1773504611000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/advance-article\/doi\/10.1093\/postmj\/qgag031\/8524061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgag031","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"article-number":"qgag031"}}